Form D · Biotechnology

Anthera Pharmaceuticals Inc

Hayward, CA · CIK 0001316175

Offering snapshot reported Jan 11, 2018 · SEC filing

Reported sold: $15M
Investors reported: 21
Minimum accepted: $0
First sale: Oct 27, 2017

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$2,883,421 → $15,000,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 11, 2018	Amendment	$15,000,000	$12,116,579vs Nov 9, 2017	21	SEC filing
Nov 9, 2017	Initial	$2,883,421	No comparison	21	SEC filing
Sep 12, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
Feb 29, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
Dec 26, 2006	Paper	Not reported	No comparison	Not reported	SEC filing
Aug 17, 2006	Paper	Not reported	No comparison	Not reported	SEC filing
Jan 31, 2005	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $1.15M
Finders' fees: $0
Form D file number: 021-298435

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Piper Jaffray & Co.	665

Source: Form D, filed Jan 11, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
May Liu	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

25801 Industrial Boulevard, Suite B
Hayward, CA, 94545